Delivery Order SPE2DB24D3013-SPE2DB25FFQFD
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $4,601.28 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract is competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of September 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a delivery order valued at $26,739.67 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award status. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $12,886.63 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract is a firm fixed price delivery order with an ultimate completion date of June 20, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,054.35 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of April 22, 2025. This competitive, non-set-aside award reflects the agency's procurement of critical pharmaceutical supplies for military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a key vendor for...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $4,917.74 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a small-value transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,997.60 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,092.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued on September 8, 2025, and represents a firm fixed-price pharmaceutical supply transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQFDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,274.97 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive award, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The delivery order fulfills critical medical commodity needs for diabetes management and reflects AmerisourceBergen Drug Corp's established capability to meet federal procurement requirements through open competition across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/5/25 |